Form 4: Athira Pharma CFO Reports Stock Transactions

Athira Pharma's Chief Financial Officer, Robert Renninger, reported recent acquisitions of common stock through an employee plan and a sale of shares to cover tax obligations related to RSU vesting.

Summary

• Chief Financial Officer Robert Renninger acquired 1,000 shares of Athira Pharma common stock on November 18, 2025, through the company's Employee Stock Purchase Plan (ESPP) at a price of $2.31 per share.
• On December 31, 2025, 1,236 Restricted Stock Units (RSUs) vested and converted into common stock.
• On January 2, 2026, 297 shares of common stock were sold at a weighted-average price of $6.88 to cover tax withholding and remittance obligations in connection with the RSU vesting.
• The reported share numbers have been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025.
• Shares received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025.

Sentiment

Score: 6

Explanation: The filing details routine insider transactions, including an employee stock purchase and a non-discretionary sale to cover taxes from RSU vesting. The CFO's participation in the ESPP is a minor positive, while the tax-related sale is neutral. The mention of a lock-up agreement from a recent private placement is a factual detail without immediate sentiment impact.

Positives

• CFO Robert Renninger's participation in the Employee Stock Purchase Plan (ESPP) by acquiring 1,000 shares indicates continued alignment with shareholder interests and confidence in the company.
• The vesting of Restricted Stock Units (RSUs) represents a planned compensation event for the executive.

Negatives

• The sale of 297 shares, even if for tax purposes, reduces the direct beneficial ownership of the Chief Financial Officer.

Risks

• Shares received upon RSU settlement are subject to a lock-up agreement from a December 2025 private placement, which could introduce future selling pressure once the lock-up period expires.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the details of the RSU vesting schedule and the lock-up agreement on certain shares.

Management Comments

• "The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan."
• "Represents shares of common stock sold to cover tax withholding and remittance obligations... and does not represent a discretionary sale by the reporting person."

Industry Context

This filing is a standard insider transaction report (Form 4) for a biotechnology company. Such reports are common across all industries and provide transparency into executive stock ownership changes, which can sometimes signal management's confidence or concerns, though in this case, the transactions are largely routine compensation and tax-related events.

Comparison to Industry Standards

• Not applicable as this filing details individual insider transactions rather than company performance metrics or project results that would be compared to industry benchmarks.

Stakeholder Impact

• Shareholders: Provides transparency on insider holdings and transactions, confirming the CFO's participation in employee stock plans and the impact of a recent private placement's lock-up on certain shares.
• Employees: Highlights the availability and utilization of the Employee Stock Purchase Plan (ESPP) and Restricted Stock Units (RSUs) as components of executive compensation.

Next Steps

• Monitoring the expiration of the lock-up agreement on shares received from RSU settlement, which could impact future trading activity.

Key Dates

Recommendation

This Form 4 filing primarily details routine insider transactions, including an employee stock purchase and a non-discretionary sale to cover tax obligations related to RSU vesting. While the CFO's participation in the ESPP is a minor positive, these transactions do not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The mention of a lock-up agreement from a December 2025 private placement is a factual update but doesn't alter the fundamental investment thesis based solely on this filing. Therefore, a "hold" recommendation is appropriate as there's no new information to suggest a change in outlook.

Keywords

Athira Pharma, ATHA, Form 4, Insider Trading, Stock Purchase Plan, Restricted Stock Units, CFO, Robert Renninger, Biotechnology, Pharmaceuticals, Reverse Stock Split